amgen glp-1 drug Study predicts 16 new obesity drugs may come to market Amgen CEO: weight loss drug
Description
It is intriguing that the Phase IIb exenatide study saw a motor benefit, but limited non-motor improvements, and now this study has a significant non-motor result, but mixed motor results
Y.HsiehM
second-generation, long-acting agents include liraglutide and semaglutide, with the latter demonstrating notable efficacy in weight reduction and neuroprotection
Especially once tens of millions of people are on them
No other available medication produces comparable results
